| Literature DB >> 32624695 |
Abhishek Suwal1, Ji-Long Hao1, Dan-Dan Zhou2, Xiu-Fen Liu1, Raja Suwal3, Cheng-Wei Lu1.
Abstract
Dry Eye Disease (DED) is a common ocular condition that needs prompt diagnosis and careful treatment interventions. If left untreated, it can lead to numerous sight-threatening complications, including ulceration of the cornea, blepharitis, alterations of the tear film, conjunctivitis, and in severe cases, may lead to scarring, thinning, and even perforation of the cornea. Intense pulsed light (IPL) is a non-laser high-intensity light source that has shown to play a valuable role in dry eye disease. Recent evidence from various research works has shown that IPL modifies the mechanism of meibomian gland dysfunction (MGD), which helps to relieve the symptoms of DED. In this review, we demonstrated the mechanism of action of IPL, including its benefits on DED. The emerging evidence shows that the role of IPL in DED is novel and therapeutic. These results direct us to conclude that IPL is a potentially beneficial tool and essential future therapy for dry eye disease. Advances in the treatment of DED will lead to a better quality of life. However, tools to recognize potentially severe side effects of DED earlier in order to treat or prevent them must be developed. © The author(s).Entities:
Keywords: dry eye disease; intense pulsed light; mechanism of action; meibomian gland dysfunction; meibum
Mesh:
Year: 2020 PMID: 32624695 PMCID: PMC7330664 DOI: 10.7150/ijms.44288
Source DB: PubMed Journal: Int J Med Sci ISSN: 1449-1907 Impact factor: 3.738
Summary of studies on IPL for DED Therapy
| Year | Design | Patients (n) | IPL sessions (n) | Dry eye symptom | BUT | Meibomian function | Reference |
|---|---|---|---|---|---|---|---|
| 2020 | Prospective randomised double-masked placebo-controlled | 58 | 5 | Improved OSDI, SPEED, SANDE | Improved | Improved | |
| 2020 | Prospective randomized double-masked sham-controlled | 114 | 3 | Improved OSDI | Improved | Improved | |
| 2020 | Prospective controlled | 29 | 3 | Improved OSDI | Improved | Improved | |
| 2020 | Retrospective | 43 | Mild group: 2; Moderate group: 3;Severe group: 4 | Improved OSDI in mild and moderate atrophy patients, not severe ones | Improved in mild and moderate atrophy patients, not in severe ones | Improved in mild and moderate atrophy patients, not in severe ones | |
| 2019 | Prospective controlled | 45 | 3 | Improved SPEED | Improved | Improved | |
| 2019 | Prospective controlled | 45 | 8 | Improved SPEED | Improved | Improved | |
| 2019 | Prospective controlled | 12 | 1 | Improved OSDI | Improved | - | |
| 2019 | Prospective comparative | 40 | 3 | Improved OSDI | Improved | - | |
| 2019 | Prospective noncomparative | 30 | 3 | Improved OSDI | Improved | Improved | |
| 2019 | Prospective noncomparative | 19 | 3 | Subjective symptoms | Improved | No statistically significant changed | |
| 2019 | Prospective noncomparative | 30 | 3 | Improved OSDI | Improved | Improved | |
| 2019 | Case-control | 82 | 1 | Improved OSDI | Improved | Improved | |
| 2019 | Retrospective | 28 | 3 | Subjective symptoms improved | Improved | Improved | |
| 2019 | Retrospective | 25 | - | Improved OSDI | Improved | Improved | |
| 2018 | Prospective, randomized, double-masked, controlled | 44 | 3 | Improved SPEED | Improved | Improved | |
| 2018 | Prospective controlled randomized | 28 | 3 | Improved SPEED | Improved | Improved | |
| 2018 | Prospective noncomparative | 31 | 4-8 | Improved SPEED | Improved | Improved | |
| 2018 | Prospective noncomparative | 26 | 3 | Subjective symptoms improved | Improved | - | |
| 2018 | Prospective noncomparative | 17 | 4 | Improved OSDI | Improved | Improved | |
| 2018 | Prospective Cohort | 35 | 3 | Improved OSDI | Improved | Improved | |
| 2017 | Prospective, randomized, double-masked, controlled | 44 | 3 | Improved OSDI, SPEED | Improved | Improved | |
| 2017 | Prospective, randomized, double-masked, controlled | 44 | 3 | Improved SPEED with no statistical difference | Improved | Improved | |
| 2017 | Prospective interventional | 40 | 4 | Improved SPEED | Improved | Improved | |
| 2017 | Prospective noncomparative | 36 | 4 | - | Improved | - | |
| 2016 | Prospective, open label | 40 | 4 | Subjective symptoms improved | Improved | Improved | |
| 2016 | Retrospective | 100 | 4 | Improved OSDI | Improved | Improved | |
| 2015 | Prospective controlled | 28 | 3 | Improved OSDI, SPEED | Improved | - | |
| 2015 | Retrospective noncomparative case series | 91 | 7 | Subjective symptoms improved | Improved | - |
Summary of Reviewed Articles on the tear film and inflammatory markers
| Study | Design | Patients (n) | IPL sessions (n) | Inflammatory marker | Tear protein and lipid | Tear film |
|---|---|---|---|---|---|---|
| Ahmed et al., | Prospective controlled | 12 | 1 | Prevent inflammatory mediator secretion | Improved | Lipid concentration of tear film improved |
| Arita et al., | Prospective controlled | 45 | 8 | IL-6, IL-17A, prostaglandin E2 | Improved | Improved homeostasis of the tear film |
| Choi et al., | Prospective noncomparative | 30 | 3 | IL-4, IL-6, IL-10, IL-17A, and TNF-α | Improved | Tear film break-up significantly improved after treatment. |
| Liu et al., | Prospective, randomized, double-masked, controlled | 44 | 3 | IL-6, IL-17A, prostaglandin E2 | The correlation between the expression of IL-17A, IL-6 in protein levels showed no statistically significant | Improved tear film quality |
| Karaka et al., | Prospective noncomparative | 26 | 3 | IL-6, IL-17A, prostaglandin E2 | Improved | Significant improvement in tear film quality |
| Seo et al., | Prospective noncomparative | 17 | 4 | Down-regulated | Improved | Instability resolved |
| Gao et al., | Case-control | 82 | 1 | IL-6, IL-17A, and IL-1β | Improved | Improve tear film (TBUT) |